Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-09-10-Speech-1-250-000"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20120910.29.1-250-000"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spoken text |
"Madam President, just to respond to Ms Grossetête, I agree that the issue of off-label use is extremely important, but I felt we needed a more in-depth discussion on the many aspects of it and I hope we will find some time in our committee to look again at this issue.
On the drug fact box, I think Mr Liese is correct. The problem people have is information overload. When you read it, it is more like a lawyer’s list to get companies off the hook if anything goes wrong, which is a list of anything that could go wrong. So people do not believe the patient information leaflets, they are not useful to patients, and we do urgently need to look at this problem again.
But, finally, one special thank you I want to make is to my researcher, Ms Hanks, who has put in a tremendous amount of work over the last two-and-half years on this whole dossier of pharmacovigilance and she, like all our assistants, works extremely hard on our behalf and on behalf of the people of Europe, and often they are not so recognised in the work that we do."@en1
|
| lpv:spokenAs | |
| lpv:unclassifiedMetadata | |
| lpv:videoURI |
Named graphs describing this resource:
The resource appears as object in 2 triples